

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q94143

Ikuo MORITA, et al.

Appln. No.: 10/574,687

Group Art Unit: 1636

Confirmation No.: 3712

Examiner: not yet assigned

Filed: April 5, 2006

For: METHOD OF CONSTRUCTING ARTIFICIAL CELL TISSUE AND BASE MATERIAL  
THEREOF

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. U.S. Patent No. 5,721,131 issued February 24, 1998, to Rudolph et al.
2. EP 1 246 011 A published October 2, 2002, to Dainippon Printing Co., Ltd. This reference was previously listed on a PTO/SB/08 A & B submitted on April 5, 2006.
3. EP 1 260 863 A1 published November 27, 2002, to Scandinavian Micro Biodevices.
4. EP 1 199 354 A1 published April 24, 2002, to Sony International and Max Planck Gesellschaft.

5. A. Kobayashi, et al., "*In vitro* formation of capillary networks using optical lithographic techniques", *Biochemical and Biophysical Research Communications*, Vol. 358, No. 3, July 6, 2007, pp. 692-697.


One copy of each of the listed documents, except Ref. 1 and 2, above is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

  
John T. Callahan  
Registration No. 32,607

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: October 19, 2007